LEADS BIOLABS-B(09887): China Securities Regulatory Commission issues filing notice for full circulation of H shares and company's plan to implement H share full circulation plan.

LEADS BIOLABS-B (09887) announces that the company has submitted an application to the China Securities Regulatory Commission on behalf of 23 company shareholders, to convert a total of 44.3916 million shares held by the 23 shareholders into H shares. On May 7, 2026, the company received a notification from the China Securities Regulatory Commission dated April 27, 2026 regarding the "full circulation" of the unlisted shares of Nanjing Weili Zhibo Biological Technology Co., Ltd. According to the notification, if the company fails to complete the conversion and listing within 12 months from the date of issuance of the notification, it should update the filing materials if it intends to continue the process. On May 8, 2026, the company further submitted filing materials to the China Securities Regulatory Commission for the conversion of 1.2215 million unlisted shares held by one shareholder into H shares. The company will apply to the Stock Exchange for conversion and listing, which must be completed after the completion of the relevant procedures set by the Stock Exchange and other relevant regulatory authorities. According to the company's articles of association, an additional shareholders' meeting is not necessary for the approval of the conversion and listing.